Search This Blog

Thursday, December 8, 2022

Akero NASH therapy gets breakthrough tag

 Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks

https://finance.yahoo.com/news/efruxifermin-granted-fda-breakthrough-therapy-120000101.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.